The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. (Q40050634)
Jump to navigation
Jump to search
scientific article published on 27 January 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. |
scientific article published on 27 January 2016 |
Statements
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma (English)
Mariusz A Wasik
Carl H June
Olga Shestova
Joseph A Fraietta
Sohail Qayyum
Qian Zhang
Marcela V Maus
Xiaobin Liu
Selene Nunez-Cruz
Michael Klichinsky
Omkar U Kawalekar
Michael Milone
Anthony Mato
Stephen J Schuster
Michael Kalos